HealthQuill ALS
The European Commission has granted marketing approval for Biogen Inc.’s therapy for the treatment of a form of amyotrophic lateral sclerosis.
Drugs Health Pharma

Biogen’s ALS drug gets European Commission’s marketing nod

The European Commission has granted marketing approval for Biogen Inc.’s therapy for the treatment of a form of amyotrophic lateral sclerosis.

Read More
Amylyx Pharmaceuticals announced it has started a process with the USFDA and Health Canada to voluntarily discontinue the marketing authorisations for its amyotrophic lateral sclerosis (ALS) therapy after the drug failed in a last-stage trial.
Drugs Health Pharma

Amylyx Pharma pulls out ALS therapy drug from US, Canada

HQ Team April 4, 2024: Amylyx Pharmaceuticals announced it has started a process with the USFDA and Health Canada to voluntarily discontinue the.

Read More
Drugs Medical Pharma

Promising new treatment on the horizon for ALS

HQ Team February 1, 2024: Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease is a rare neurodegenerative disorder affecting both upper.

Read More
The US Food and Drug Administration has cleared Biogen Inc’s drug, branded as Qalsody, to treat amyotrophic lateral sclerosis (ALS), an aggressive and rare form of the disease in adults.
Drugs Health Medical Pharma

Biogen’s sclerosis drug gets FDA’s fast approval clearance

HQ Team April 26, 2023: The US Food and Drug Administration has cleared Biogen Inc’s drug, branded as Qalsody, to treat amyotrophic lateral.

Read More
AI drug
Drugs Pharma

Verge Genomics starts human trials with AI drug

Verge Genomics, backed by Eli Lilly and Merck & Co., announced it had dosed a human during clinical trials with a drug discovered.

Read More